The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

PURPOSE: Bortezomib is an important agent in multiple myeloma treatment, but resistance in cell lines and patients has been described. The main mechanisms of resistance described in cancer fall into one of two categories, pharmacokinetic resistance (PK), e.g. over expression of drug efflux pumps and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Chemother Pharmacol
Main Authors: O’Connor, Robert, Ooi, Melissa G., Meiller, Justine, Jakubikova, Jana, Klippel, Steffen, Delmore, Jake, Richardson, Paul, Anderson, Kenneth, Clynes, Martin, Mitsiades, Constantine S., O’Gorman, Peter
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414393/
https://ncbi.nlm.nih.gov/pubmed/23589314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2136-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki